Extended Endocrine Therapy: Who Will Benefit?

02_03 Adjuvant endocrine therapy for early breast cancerПодробнее

BCI: Guideline-Recognized and Validated to Help Guide Extended Endocrine DecisionsПодробнее

De-escalating N1 patients not likely to benefit from extended endocrine therapyПодробнее

Partnering to Provide Personalized Care: Patient Selection for Extended Endocrine TherapyПодробнее

JADPRO Live 2023 - Standardizing Extended Endocrine Therapy Decision-MakingПодробнее

View the Data on Extended Endocrine TherapyПодробнее

BCI: A Unique, Guideline-Recognized Test to Predict Benefit of Extended Endocrine TherapyПодробнее

Education Session: Trends in Adjuvant Endocrine TherapyПодробнее

De-escalate patients who are unlikely to benefit from extended endocrine therapyПодробнее

The Predictive Power of the Breast Cancer Index (H/I) Biomarker-SABCS 2022Подробнее

Dr. VK Gadi: Guideline Updates for Extended Endocrine Therapy Decision-MakingПодробнее

MOASC Clinical Webinar - Breast Cancer 2/9/23Подробнее

Optimizing adjuvant endocrine therapy for early Breast CancerПодробнее

BCI as a Predictive Biomarker for Extended Endocrine Therapy BenefitПодробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

Dr. Reshma Mahtani: Guideline Updates for Extended Endocrine Therapy Decision-MakingПодробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

PD15 Defining molecular markers of endocrine resistance in clinic Komal JhaveriПодробнее

Standardizing Extended Endocrine Therapy RecommendationsПодробнее